TME Pharma N.V. (ALTME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TME Pharma N.V. (ALTME) has a cash flow conversion efficiency ratio of 0.353x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-557.00K ≈ $-651.19K USD) by net assets (€-1.58 Million ≈ $-1.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TME Pharma N.V. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
TME Pharma N.V. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how TME Pharma N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
TME Pharma N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TME Pharma N.V. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peregrine Gold Ltd
AU:PGD
|
-0.334x |
|
Noble Financials SA
WAR:IBS
|
0.003x |
|
Mathios Refractories S.A.
AT:MATHIO
|
0.009x |
|
Spectrumone publ AB
ST:SPEONE
|
-0.116x |
|
Sedania Innovator Bhd
KLSE:0178
|
0.056x |
|
Mount Burgess Mining NL
AU:MTB
|
0.097x |
|
Johan Holdings Bhd
KLSE:3441
|
-0.016x |
|
YB Ventures Bhd
KLSE:5048
|
-0.023x |
Annual Cash Flow Conversion Efficiency for TME Pharma N.V. (2014–2025)
The table below shows the annual cash flow conversion efficiency of TME Pharma N.V. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of TME Pharma N.V..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-1.58 Million ≈ $-1.85 Million |
€-3.42 Million ≈ $-3.99 Million |
2.164x | +175.37% |
| 2024-12-31 | €1.61 Million ≈ $1.89 Million |
€-4.63 Million ≈ $-5.42 Million |
-2.871x | -114.98% |
| 2023-12-31 | €-294.00K ≈ $-343.72K |
€-5.63 Million ≈ $-6.59 Million |
19.167x | +100.77% |
| 2022-12-31 | €-1.27 Million ≈ $-1.49 Million |
€-12.14 Million ≈ $-14.20 Million |
9.546x | +447.13% |
| 2021-12-31 | €4.50 Million ≈ $5.26 Million |
€-12.38 Million ≈ $-14.47 Million |
-2.750x | -305.25% |
| 2020-12-31 | €7.70 Million ≈ $9.00 Million |
€-5.22 Million ≈ $-6.11 Million |
-0.679x | -129.36% |
| 2019-12-31 | €-1.85 Million ≈ $-2.17 Million |
€-4.29 Million ≈ $-5.01 Million |
2.312x | +50.67% |
| 2018-12-31 | €-2.61 Million ≈ $-3.05 Million |
€-4.00 Million ≈ $-4.68 Million |
1.534x | +41.92% |
| 2017-12-31 | €-3.92 Million ≈ $-4.58 Million |
€-4.24 Million ≈ $-4.95 Million |
1.081x | -70.15% |
| 2016-12-31 | €-2.48 Million ≈ $-2.90 Million |
€-8.99 Million ≈ $-10.51 Million |
3.622x | +88.94% |
| 2015-12-31 | €-7.03 Million ≈ $-8.22 Million |
€-13.48 Million ≈ $-15.76 Million |
1.917x | -3.93% |
| 2014-12-31 | €-6.24 Million ≈ $-7.30 Million |
€-12.46 Million ≈ $-14.57 Million |
1.996x | -- |
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more